Arecor Therapeutics Stock Forecast

Stock Price Forecast

According to 2 analysts polled by S&P Global, Arecor Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of 276p. The average 1-year stock price forecast is 299.28% higher than the current stock price, while the lowest is 251p (+263.77%) and the highest is 300p (+334.78%).

Price Target: 276p (+299.28%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	251p	276p	276p	300p
Change	+263.77%	+299.28%	+299.28%	+334.78%

Analyst Ratings

The average analyst rating for Arecor Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26	May '26
Strong Buy	2	2	2	2	2	2
Buy	0	0	0	0	0	0
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	2	2	2	2	2	2

Financial Forecast

Revenue This Year

878.50K

from 1.71M

-48.75%

from 1.71M

Revenue Next Year

1.05M

from 878.50K

19.52%

from 878.50K

EPS This Year

-0.15

from 0.02

EPS Next Year

-0.11

from -0.15

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	1.16M	2.40M	4.57M	1.64M	1.71M	878.50K
Revenue Growth	-31.80%	107.51%	90.30%	-64.07%	4.32%	-48.75%
Operating Income	-5.98M	-10.34M	-9.18M	-5.18M	-4.05M	-6.20M
EPS	-	-	-	-	0.02	-0.15
Free Cash Flow	-3.60M	-7.06M	-3.00M	-5.20M	4.88M	-4.66M
No. Analysts	-	-	-	-	-	2

EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is GBP.

Revenue Forecast

Revenue	2026	2027
High	900,000
Avg	878,500
Low	857,000

Revenue Growth

Revenue Growth	2026	2027
High	-47.5%
Avg	-48.7%
Low	-50.0%

EPS Forecast

EPS	2026	2027
High	-
Avg	-0.15
Low	-

EPS Growth

EPS Growth	2026	2027
High	-
Avg	-
Low	-